Article
Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
European journal of clinical investigation - 1 Apr 1993
Klausen I C, Gerdes L U, Meinertz H, Hansen F A, Faergeman O
Abstract excerpt
HMG-CoA reductase inhibitors effectively reduce the concentration of low density lipoproteins (LDL) in plasma. Lipoprotein(a) [Lp(a)] may be as atherogenic as LDL. A few studies, only one of which was placebo controlled, suggest that the HMG CoA reductase inhibitors either do not affect Lp(a) or...
Topics
- Adult
- Aged
- Apolipoproteins A
- Bile Acids and Salts
- Double-Blind Method
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hyperlipoproteinemia Type II
- Lipids
- Lipoprotein(a)
- Male
- Middle Aged
- Phenotype
- Polymorphism, Genetic
- Pravastatin